Mercodia AB

Mercodia AB announces collaboration with Finnish HyTest on commercialization of new cardiovascular risk marker

Press Release   •   Dec 16, 2013 09:49 CET

UPPSALA, SWEDEN, December 16, 2013 – Mercodia AB has today signed a licensing agreement with HyTest Finland, which gives Sweden-based Mercodia exclusive rights to develop, manufacture and sell research assays using HyTest's patented IGFBP-4 fragment technology. Initial studies have shown that detection of IGFBP-4 fragments could serve as a predictor of near-term risk of acute coronary syndromes and stroke.

                                                                                                        

"There is an increasing need for new risk markers in cardiovascular disease", says Mona Österberg (CEO of Mercodia AB). She adds, "HyTest's IGFBP-4 fragment technology is a new tool with great potential and the collaboration with HyTest offers the possibility to be in the front line of CVD diagnostics development".

 

Maria Severina (CEO of HyTest) comments, "Bringing new diagnostic markers to the market is increasingly demanding and requires scientific studies to evaluate the value of a new marker". She adds, "It is essential that these studies are done using high quality assays and kits. Because of this requirement, we chose to work with Mercodia. In addition, their existing product portfolio overlaps with our new technology and this creates valuable synergies.”

_____________________________________________________________________________________

 

About Mercodia AB

Mercodia AB is a Swedish biotech company focusing on the development of highly reproducible and specific ELISA assays within the field of metabolic disorders.  Mercodia is a world-leading supplier to all major international markets and provides a professional scientific support system to develop unique diagnostics for emerging markets as well as novel applications for existing products. The facilities include a GLP-compliant laboratory and a customized assay development core managed by an extensive quality system and ISO 13485 for manufacturing medical devices.

 

About HyTest Finland

Finland-based HyTest manufactures monoclonal antibodies and antigens, which are key raw materials used by the IVD industry for their laboratory tests and kits. HyTest is the leading provider of certain cardiac, metabolic syndrome and infectious diseases detection-related raw materials and its primary customers are industrial IVD companies and the research community worldwide.

 

_____________________________________________________________________________________________

 

For more information contact:

 

Jeanette Axelsson, Mercodia, Tel: +46 18 57 00 97, Email: jeanette.axelsson@mercodia.com

Pekka Hildén, HyTest, Tel: +358-2-512 0904, Email: pekka.hilden@hytest.fi

                                                                                                 

Mercodia is a world-leading developer, manufacturer and distributor of high quality immunoassay kits. We specialize in ELISA assays for clinical as well as research applications, notably within diabetes, obesity and cardiovascular disease. We offer assays applicable in both human and animal models. For more information visit www.mercodia.com.